{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:46:28Z","timestamp":1760121988298,"version":"build-2065373602"},"reference-count":15,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T00:00:00Z","timestamp":1672963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Fundamental Research Funds for the Central Universities of China","award":["WK9110000003"],"award-info":[{"award-number":["WK9110000003"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: This study aimed to evaluate whether the addition of hypomethylating agents (HMA) to low-intensity chemotherapy can enhance the clinical efficacy of induction treatment for elderly acute myeloid leukemia (AML) patients who are unsuitable for standard induction therapy. Materials and Methods: This study retrospectively analyzed 117 patients over 60 years old who were initially diagnosed with AML and received low-intensity induction treatment in the Department of Hematology in Anhui provincial hospital from January 2015 to December 2020. Twenty-three patients were excluded, and the remaining 94 patients were divided into two groups according to the selection of induction regimens. Results: Forty-four patients received HMA combined with low-intensity chemotherapy, and the other 50 patients received only low-intensity induction chemotherapy. Forty-three patients (45.7%) obtained complete remission (CR) after the initial induction treatment. The CR rate in the HMA plus low-intensity chemotherapy group was 34.1% (15\/44), and in the single low-intensity chemotherapy group was 56.0% (28\/50) (p = 0.04). The 30 days cumulative early death rates were 9.1% (95% CI: 3.5\u201322.4%) in the HMA plus low-intensity chemotherapy group and 6.0% (95% CI: 2.0\u201317.5%) in the single low-intensity chemotherapy group, respectively (p = 0.59), and the one-year cumulative relapse rates were 21.1% (95% Cl: 9.8\u201341.9%) and 33.3% (95% Cl: 20.3\u201351.5%), respectively (p = 0.80). The one-year overall survival (OS) rates for patients in the HMA plus low-intensity chemotherapy group and the single low-intensity chemotherapy group were 37.3% (95% Cl: 23.1\u201351.5%) and 55.4% (95% Cl: 40.5\u201367.9%), respectively (p = 0.098), and the one-year event-free survival (EFS) rates were 8.5% (95% Cl: 2.2\u201320.6%) and 20.6% (95% Cl: 9.1\u201335.3%), respectively (p = 0.058). Conclusions: This study showed that the addition of HMA to low-intensity induction chemotherapy does not improve prognosis in elderly AML patients who are unsuitable for standard induction chemotherapy.<\/jats:p>","DOI":"10.3390\/medicina59010114","type":"journal-article","created":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T01:48:19Z","timestamp":1672969699000},"page":"114","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Addition of Hypomethylating Agents to Low-Intensity Induction Chemotherapy Does Not Improve Outcomes in Elderly Acute Myeloid Leukemia Patients: A Single-Center Retrospective Study"],"prefix":"10.3390","volume":"59","author":[{"given":"Dan","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Hematology, Anhui Provincial Hospital, WanNan Medical College, Wenchang Xi Road No. 22, Wuhu 241002, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Lujiang Road No. 17, Hefei 230001, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Tong","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Lujiang Road No. 17, Hefei 230001, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Lujiang Road No. 17, Hefei 230001, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erling","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Lujiang Road No. 17, Hefei 230001, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziwei","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Lujiang Road No. 17, Hefei 230001, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Xue","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Lujiang Road No. 17, Hefei 230001, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuhan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Lujiang Road No. 17, Hefei 230001, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangyu","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Lujiang Road No. 17, Hefei 230001, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1976-6415","authenticated-orcid":false,"given":"Changcheng","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Hematology, Anhui Provincial Hospital, WanNan Medical College, Wenchang Xi Road No. 22, Wuhu 241002, China"},{"name":"Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Lujiang Road No. 17, Hefei 230001, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","article-title":"Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges","volume":"36","author":"Shallis","year":"2019","journal-title":"Blood Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4840","DOI":"10.1182\/blood-2012-06-436055","article-title":"Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia","volume":"120","author":"Ravandi","year":"2012","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa0901409","article-title":"High-dose daunorubicin in older patients with acute myeloid leukemia","volume":"361","author":"Lowenberg","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00277-015-2351-x","article-title":"Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States","volume":"94","author":"Medeiros","year":"2015","journal-title":"Ann. Hematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.3324\/haematol.2012.066100","article-title":"Survival for older patients with acute myeloid leukemia: A population-based study","volume":"97","author":"Oran","year":"2012","journal-title":"Haematologica"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"6653","DOI":"10.1158\/1078-0432.CCR-21-2139","article-title":"Clinical Trials Assessing Hypomethylating Agents Combined with Other Therapies: Causes for Failure and Potential Solutions","volume":"27","author":"Zavras","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1126\/science.aam7304","article-title":"The cancer epigenome: Concepts, challenges, and therapeutic opportunities","volume":"355","author":"Dawson","year":"2017","journal-title":"Science"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/leu.2012.312","article-title":"Azacitidine fails to eradicate leukemic stem\/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia","volume":"27","author":"Craddock","year":"2013","journal-title":"Leukemia"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41375-018-0312-9","article-title":"Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome","volume":"33","author":"Cortes","year":"2019","journal-title":"Leukemia"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1182\/blood-2006-04-014324","article-title":"Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: Results from AMLSG trial AML HD98-B","volume":"108","author":"Frohling","year":"2006","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.3109\/10428194.2015.1091931","article-title":"Epigenetic priming with decitabine followed by low-dose idarubicin\/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms","volume":"57","author":"Ye","year":"2016","journal-title":"Leuk. Lymphoma"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/1\/114\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:00:49Z","timestamp":1760119249000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/1\/114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,6]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["medicina59010114"],"URL":"https:\/\/doi.org\/10.3390\/medicina59010114","relation":{},"ISSN":["1648-9144"],"issn-type":[{"type":"electronic","value":"1648-9144"}],"subject":[],"published":{"date-parts":[[2023,1,6]]}}}